Ipca Laboratories Ltd vs Jubilant Pharmova Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Ipca Laboratories Ltd is ₹ 1531 as of 30 Apr 15:30 . The P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 yearsThe P/E Ratio of Jubilant Pharmova Ltd changed from 13 on March 2021 to 16.8 on March 2025 . This represents a CAGR of 5.26% over 5 years The Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 yearsThe Market Cap of Jubilant Pharmova Ltd changed from ₹ 10838 crore on March 2021 to ₹ 14220 crore on March 2025 . This represents a CAGR of 5.58% over 5 years The revenue of Ipca Laboratories Ltd for the Dec '25 is ₹ 2430 crore as compare to the Sep '25 revenue of ₹ 2584 crore. This represent the decline of -5.96% The revenue of Jubilant Pharmova Ltd for the Dec '25 is ₹ 2143 crore as compare to the Sep '25 revenue of ₹ 1976 crore. This represent the growth of 8.44% The ebitda of Ipca Laboratories Ltd for the Dec '25 is ₹ 571.19 crore as compare to the Sep '25 ebitda of ₹ 514.52 crore. This represent the growth of 11.01% The ebitda of Jubilant Pharmova Ltd for the Dec '25 is ₹ 270.2 crore as compare to the Sep '25 ebitda of ₹ 345.3 crore. This represent the decline of -21.75% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 364.05 crore over 7 quarters. This represents a CAGR of 41.23% The net profit of Jubilant Pharmova Ltd changed from ₹ 481.8 crore to ₹ 55.8 crore over 7 quarters. This represents a CAGR of -70.83% The Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 yearsThe Dividend Payout of Jubilant Pharmova Ltd changed from 37.14 % on March 2021 to 414.06 % on March 2025 . This represents a CAGR of 61.97% over 5 years .

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

About Jubilant Pharmova Ltd

Jubilant Pharmova Limited was initially incorporated as 'Vam Organic Chemicals Limited' on June 21, 1978.
Company name was changed to 'Jubliant Organosys Limited' in November, 2001 and was again changed to 'Jubilant Life Sciences Limited' in October, 2009 and further it attained a new name 'Jubilant Pharmova Limited' in February, 2021. Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA.

FAQs for the comparison of Ipca Laboratories Ltd and Jubilant Pharmova Ltd

Which company has a larger market capitalization, Ipca Laboratories Ltd or Jubilant Pharmova Ltd?

Market cap of Ipca Laboratories Ltd is 38,847 Cr while Market cap of Jubilant Pharmova Ltd is 14,763 Cr

What are the key factors driving the stock performance of Ipca Laboratories Ltd and Jubilant Pharmova Ltd?

The stock performance of Ipca Laboratories Ltd and Jubilant Pharmova Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ipca Laboratories Ltd and Jubilant Pharmova Ltd?

As of May 3, 2026, the Ipca Laboratories Ltd stock price is INR ₹1531.2. On the other hand, Jubilant Pharmova Ltd stock price is INR ₹926.75.

How do dividend payouts of Ipca Laboratories Ltd and Jubilant Pharmova Ltd compare?

To compare the dividend payouts of Ipca Laboratories Ltd and Jubilant Pharmova Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.